Company news

INmune Bio Inc. news in 2021

INmune Bio Inc.'s news releases, calls and decks from 2021, newest first.

View company

INmune Bio, Inc. Announces Key Breast Cancer Treatment Resistance Data to be Presented at the 2021 San Antonio Breast Cancer Symposium

December 8, 2021

INmune Bio, Inc. Announces Two Presentations at the 2021 British Society of Immunology Congress and Provides 119-day data on First patient in MDS trial.

November 30, 2021

INmune Bio, Inc. Announces Third Quarter 2021 Results and Provides Business Update

November 2, 2021

INmune Bio, Inc. Announces Multiple Oral and Poster Presentations at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting

October 26, 2021

INmune Bio, Inc. to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, November 3

October 24, 2021

INmune Bio, Inc. Announces Participation at Upcoming Investor Conferences

September 19, 2021

Alzheimer’s Patients Treated with INmune Bio’s XPro™ Show Reduction in CSF Phospho-Tau and Evidence of Remyelination

August 31, 2021

INmune Bio, Inc. Announces Biomarker Data Demonstrating that the First Patient Treated with its NK Cell Priming “Pseudokine”, INKmune™, Successfully Produced Memory-Like NK Cells

August 24, 2021

INmune Bio, Inc. Announces Second Quarter 2021 Results and Provides Business Update

August 3, 2021

INmune Bio, Inc. to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, August 4

July 27, 2021

INmune Bio, Inc. Announces Design of Upcoming Phase 2 Alzheimer’s Disease Clinical Trial and New Phase 1b AD Biomarker Data

July 25, 2021

INmune Bio acquires LUMICKS' z-Movi® Cell Avidity Analyzer to accelerate the development of its NK cell platform for cancer treatments

July 21, 2021

INmune Bio, Inc. Announces Poster Presentation and Plenary Talk at the Alzheimer’s Association International Conference 2021

July 18, 2021

INmune Bio, Inc. announces $40 million registered direct offering

July 13, 2021

INmune Bio, Inc. Announces First Patient Treated with NK cell priming “pseudokine” INKmune in High-Risk Myelodysplastic Syndrome (MDS)

July 11, 2021

INmune Bio, Inc. Announces $15 Million Credit Facility to Purchase Xencor Option to Reduce Future Dilution

June 13, 2021

INmune Bio, Inc. Announces Lead Drug Candidate XPro1595 Receives Chemical Drug Name pegipanermin from USAN

June 1, 2021

INmune Bio, Inc. Announces First Quarter 2021 Results and Provides Business Update

May 4, 2021

INmune Bio, Inc. to Report First Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, May 5

April 27, 2021

INmune Bio, Inc. Announces Participation in Fireside Chat at the B Riley Neurosciences Conference

April 25, 2021

INmune Bio, Inc. Announces Professor Mark Lowdell, PhD, CSO to Deliver Presentations at Two Upcoming Medical Meetings

March 21, 2021

INmune Bio, Inc. Announces Participation at Upcoming Virtual Investor Conferences in March 2021

March 7, 2021

INmune Bio, Inc. Announces Fourth Quarter and Full Year 2020 Results and Provides Business Update

March 3, 2021

INmune Bio, Inc. to Report Fourth Quarter and Full Year 2020 Financial Results and Provide a Corporate Update on Thursday, March 4

February 24, 2021

INmune Bio, Inc. Announces XPro1595 Found to Decrease Neuroinflammation and Neurodegeneration Biomarkers in Patients with Alzheimer’s Disease in Phase 1b Trial

January 20, 2021

Calls in 2021

Decks in 2021